Valley Wealth Managers Inc. Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Valley Wealth Managers Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 20.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 539,494 shares of the biopharmaceutical company's stock after selling 139,248 shares during the period. Valley Wealth Managers Inc.'s holdings in Pfizer were worth $14,313,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Davidson Trust Co. raised its position in shares of Pfizer by 14.6% in the fourth quarter. Davidson Trust Co. now owns 39,656 shares of the biopharmaceutical company's stock valued at $1,052,000 after buying an additional 5,062 shares during the last quarter. Atria Wealth Solutions Inc. grew its holdings in shares of Pfizer by 1.3% in the fourth quarter. Atria Wealth Solutions Inc. now owns 584,963 shares of the biopharmaceutical company's stock valued at $15,519,000 after purchasing an additional 7,544 shares during the period. Kornitzer Capital Management Inc. KS grew its holdings in shares of Pfizer by 3.6% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 1,210,009 shares of the biopharmaceutical company's stock valued at $32,102,000 after purchasing an additional 41,694 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Pfizer by 23.1% in the fourth quarter. Venturi Wealth Management LLC now owns 6,181 shares of the biopharmaceutical company's stock valued at $164,000 after purchasing an additional 1,159 shares during the period. Finally, Citizens & Northern Corp grew its holdings in shares of Pfizer by 7.5% in the fourth quarter. Citizens & Northern Corp now owns 36,646 shares of the biopharmaceutical company's stock valued at $972,000 after purchasing an additional 2,545 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.6 %

NYSE:PFE traded up $0.42 during mid-day trading on Friday, hitting $26.32. The stock had a trading volume of 54,560,140 shares, compared to its average volume of 38,524,395. The stock has a 50-day simple moving average of $26.30 and a two-hundred day simple moving average of $27.42. The company has a market capitalization of $149.14 billion, a PE ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.54%. Pfizer's dividend payout ratio (DPR) is 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Guggenheim reissued a "buy" rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.